HCW Biologics Stock (NASDAQ:HCWB)

Revenue Ownership Financials Chart

Previous Close

$4.26

52W Range

$3.55 - $100.80

50D Avg

$5.68

200D Avg

$12.89

Market Cap

$10.28M

Avg Vol (3M)

$786.59K

Beta

0.65

Div Yield

HCWB Company Profile

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Jul 20, 2021

Website

HCWB Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Mar 25
Operating Segments	$5.07K

Fiscal year ends in Dec 24 | Currency in USD

HCWB Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$2.57M	$2.84M	$6.72M
Operating Income	$-29.48M	$-25.72M	$-15.08M
Net Income	$-30.02M	$-24.99M	$-14.72M
EBITDA	$-29.48M	$-23.58M	$-14.18M
Basic EPS	$-0.77	$-0.70	$-0.41
Diluted EPS	$-0.77	$-0.70	$-0.41

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
CSBR	Champions Oncology, Inc.
MOLN	Molecular Partners AG
RNAZ	TransCode Therapeutics, Inc.
ABVC	ABVC BioPharma, Inc.
MNOV	MediciNova, Inc.
EVAX	Evaxion Biotech A/S
CLYM	Climb Bio, Inc.
KTTA	Pasithea Therapeutics Corp.
RNXT	RenovoRx, Inc.